Lilly’s Ixekizumab Results More Than Skin Deep In Psoriasis Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma presented positive Phase III data for the psoriasis drug when compared with placebo and the current standard of care, Amgen’s Enbrel. Lilly plans to submit the IL-17 inhibitor for approval by mid-2015.
You may also be interested in...
IL-17: Pushing The Limits Of A Drug Target
A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.